# Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia

> **NCT02709083** · PHASE2 · TERMINATED · sponsor: **Emory University** · enrollment: 7 (actual)

## Conditions studied

- Chronic Myelogenous Leukemia
- Chronic Myeloid Leukemia
- Leukemia

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Imatinib Mesylate
- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT02709083
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10
- **Primary completion:** 2018-07
- **Final completion:** 2018-07
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Original principal investigator left institution
- **Last updated:** 2018-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02709083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02709083, "Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02709083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*